OTCMKTS:TKPYY - Takeda Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.94 -0.58 (-2.70 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$20.94
Today's Range$20.92 - $21.38
52-Week Range$15.50 - $31.29
Volume1.55 million shs
Average Volume5.90 million shs
Market Capitalization$32.72 billion
P/E Ratio12.11
Dividend Yield3.48%
Beta0.42
Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreement with Samsung Bioepis Co., Ltd. to co-develop various biologic therapies; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as drugs for neglected diseases initiative; and Molecular Templates to develop CD38-targeted engineered toxin bodies. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Receive TKPYY News and Ratings via Email

Sign-up to receive the latest news and ratings for TKPYY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TKPYY
CUSIPN/A
CIKN/A
Phone816-6204-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.99 billion
Cash Flow$2.7846 per share
Book Value$11.62 per share

Profitability

Net Income$1.68 billion

Miscellaneous

EmployeesN/A
Outstanding Shares1,562,360,000
Market Cap$32.72 billion
Next Earnings DateN/A
OptionableNot Optionable

Takeda Pharmaceutical (OTCMKTS:TKPYY) Frequently Asked Questions

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

Has Takeda Pharmaceutical been receiving favorable news coverage?

Media stories about TKPYY stock have trended somewhat negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Takeda Pharmaceutical earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Pfizer (PFE), Allena Pharmaceuticals (ALNA), OrganiGram (OGRMF), Shire (SHPG), Syndax Pharmaceuticals (SNDX), Canopy Growth (CGC), Clearside Biomedical (CLSD) and Resonant (RESN).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 52)
  • Mr. Andrew S. Plump M.D., Ph.D., Chief Medical & Scientific Officer and Director
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer
  • Mr. Haruhiko Hirate, Member of Management Board and Corp. Communications & Public Affairs Officer

How do I buy shares of Takeda Pharmaceutical?

Shares of TKPYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TKPYY stock can currently be purchased for approximately $20.94.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $32.72 billion and generates $15.99 billion in revenue each year.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is http://www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111.


MarketBeat Community Rating for Takeda Pharmaceutical (OTCMKTS TKPYY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TKPYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TKPYY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Trading Strategy

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel